
Warburg and Advent leading race to acquire Baxter’s €4bn biopharma unit
Warburg Pincus and Advent International are leading a private equity consortium which is in advanced discussions over the acquisition of medical device maker Baxter International Inc’s biopharma solutions business, in a deal that could be worth more than €4 billion, according to a report by the Financial Post.
